Fixation for the Treatment of Femoral Neck Fractures
Launched by HEBEI MEDICAL UNIVERSITY THIRD HOSPITAL · May 25, 2018
Trial Information
Current as of April 27, 2025
Unknown status
Keywords
ClinConnect Summary
The incidence of femoral neck fracture accounts for 3.6% of all fractures, is the most prevalent injuries which commonly encountered among older people with high mortality, morbidity and young fit healthy ones who subjected to high-energy trauma . Non-union or avascular necrosis of femoral neck fracture which lead to loss of labor capacity and death, is the most commonly occurred complication and results in considerable burden for family. The treatment is difficult and challenging, and to minimize the negative results such as limited mobilization or other complications, it is essential to t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • closed femoral neck fracture
- • no fractures at other sites
- • surgical treatment with cannulated compression screws or PFNA
- • follow-up time greater than 1 years.
- Exclusion Criteria:
- • the absence of severe cognitive dysfunction,
- • the presence of a pathological femoral neck fracture
- • previous femoral neck fracture, treated with other internal fixations and surgical treatment with open reduction.
About Hebei Medical University Third Hospital
Hebei Medical University Third Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices across various medical fields. With a commitment to ethical standards and patient safety, the institution collaborates with multidisciplinary teams to conduct rigorous clinical studies that contribute to the scientific community and enhance treatment options. Leveraging state-of-the-art facilities and a patient-centric approach, Hebei Medical University Third Hospital plays a vital role in the advancement of clinical research and the development of new healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shijiazhuang, Hebei, China
Patients applied
Trial Officials
zhiyong Hou, MD
Study Director
Hebei Medical University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials